乌苯美司联合XELOX方案治疗胃癌的疗效

摘要

目的 探讨乌苯美司联合XELOX方案治疗胃癌的疗效.方法 60例胃癌患者,随机分为观察组30例和对照组30例.观察组采用乌苯美司联合XELOX方案,对照组采用XELOX方案新辅助化疗.检测两组治疗前后T淋巴细胞亚群及NK细胞比例,比较两组治疗后疗效及不良反应发生情况.结果 观察组治疗后CD4+/CD8+及NK细胞比例高于治疗前及对照组(P＜0.05);两组治疗后CD4+和CD8+细胞比例比较差异无统计学意义(P＞0.05).两组治疗后有效率及生存率比较差异无统计学意义(P＞0.05).观察组治疗后不良反应发生率为30.00％,低于对照组的53.33％(P＜0.05).结论 与单用XELOX方案新辅助化疗比较,乌苯美司联合XELOX方案治疗胃癌更能改善机体免疫功能,减轻化疗不良反应.%Objective To investigate the efficacy of ubenimex combined with XELOX re,men in treatment of gastric cancer.Methods A total of 60 cases with gastric cancer was equally and randomly divided into two groups.Group A was treated with ubenimex combined with XELOX regimen and group B was treated with XELOX regimen alone The T-lymphocyte subsets and NK cells were detected before and after treatment.The efficacy and adverse effects were compared between two groups.Results The CD4+/CD8+ ratio and the percentage of NK cells in group A were higher after treatment than those before treatment and in group B(P＜0.05).There were no significant differences in CD4+ and CD8+ after treatment between two groups(P＞0.05).The effectiveness rate and survival rate of two groups after treatment were similar(P＞0.05).The incidence rate of adverse effects was lower in group A than that in group B(30.00％ vs.53.33％) (P＜0.05).Conclusion Compared to XELOX regimen in the treatment of gastric cancer,ubenimex combined with XELOX regimen is more effective in improving immune function and reducing adverse reactions of chemotherapy.